Literature DB >> 31958471

Electrophysiological biomarkers of antidepressant response to ketamine in treatment-resistant depression: Gamma power and long-term potentiation.

Jessica R Gilbert1, Carlos A Zarate2.   

Abstract

Over the last two decades, the discovery of ketamine's antidepressant properties has galvanized research into the neurobiology of treatment-resistant depression. Nevertheless, the mechanism of action underlying antidepressant response to ketamine remains unclear. This study reviews electrophysiological studies of ketamine's effects in individuals with depression as well as healthy controls, with a focus on two putative markers of synaptic potentiation: gamma oscillations and long-term potentiation. The review focuses on: 1) measures of gamma oscillations and power and their relationship to both acute, psychotomimetic drug effects as well as delayed antidepressant response in mood disorders; 2) changes in long-term potentiation as a promising measure of synaptic potentiation following ketamine administration; and 3) recent efforts to model antidepressant response to ketamine using novel computational modeling techniques, in particular the application of dynamic causal modeling to electrophysiological data. The latter promises to better characterize the mechanisms underlying ketamine's antidepressant effects. Published by Elsevier Inc.

Entities:  

Keywords:  Dynamic causal modeling; Electrophysiology; Gamma; Ketamine; Long-term potentiation

Mesh:

Substances:

Year:  2020        PMID: 31958471      PMCID: PMC6997043          DOI: 10.1016/j.pbb.2020.172856

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  82 in total

1.  mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.

Authors:  Nanxin Li; Boyoung Lee; Rong-Jian Liu; Mounira Banasr; Jason M Dwyer; Masaaki Iwata; Xiao-Yuan Li; George Aghajanian; Ronald S Duman
Journal:  Science       Date:  2010-08-20       Impact factor: 47.728

2.  NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons.

Authors:  Houman Homayoun; Bita Moghaddam
Journal:  J Neurosci       Date:  2007-10-24       Impact factor: 6.167

3.  Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.

Authors:  Jennifer L Phillips; Sandhaya Norris; Jeanne Talbot; Meagan Birmingham; Taylor Hatchard; Abigail Ortiz; Olabisi Owoeye; Lisa A Batten; Pierre Blier
Journal:  Am J Psychiatry       Date:  2019-03-29       Impact factor: 18.112

4.  Disinhibition of CA1 pyramidal cells by low-dose ketamine and other antagonists with rapid antidepressant efficacy.

Authors:  Allie J Widman; Lori L McMahon
Journal:  Proc Natl Acad Sci U S A       Date:  2018-03-12       Impact factor: 11.205

5.  Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression.

Authors:  Brian R Cornwell; Giacomo Salvadore; Maura Furey; Craig A Marquardt; Nancy E Brutsche; Christian Grillon; Carlos A Zarate
Journal:  Biol Psychiatry       Date:  2012-04-21       Impact factor: 13.382

Review 6.  The gabaergic hypothesis of depression.

Authors:  K G Lloyd; B Zivkovic; B Scatton; P L Morselli; G Bartholini
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1989       Impact factor: 5.067

7.  Visual sensory processing deficits in patients with bipolar disorder revealed through high-density electrical mapping.

Authors:  Sherlyn Yeap; Simon P Kelly; Richard B Reilly; Jogin H Thakore; John J Foxe
Journal:  J Psychiatry Neurosci       Date:  2009-11       Impact factor: 6.186

8.  Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.

Authors:  Adriana Feder; Michael K Parides; James W Murrough; Andrew M Perez; Julia E Morgan; Shireen Saxena; Katherine Kirkwood; Marije Aan Het Rot; Kyle A B Lapidus; Le-Ben Wan; Dan Iosifescu; Dennis S Charney
Journal:  JAMA Psychiatry       Date:  2014-06       Impact factor: 21.596

9.  Ketamine Enhances Visual Sensory Evoked Potential Long-term Potentiation in Patients With Major Depressive Disorder.

Authors:  Rachael L Sumner; Rebecca McMillan; Meg J Spriggs; Doug Campbell; Gemma Malpas; Elizabeth Maxwell; Carolyn Deng; John Hay; Rhys Ponton; Ian J Kirk; Frederick Sundram; Suresh D Muthukumaraswamy
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2019-07-23

10.  Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

Authors:  Sungho Maeng; Carlos A Zarate; Jing Du; Robert J Schloesser; Joseph McCammon; Guang Chen; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2007-07-23       Impact factor: 13.382

View more
  10 in total

1.  Pathway-specific contribution of parvalbumin interneuron NMDARs to synaptic currents and thalamocortical feedforward inhibition.

Authors:  Eastman M Lewis; Hayli E Spence; Neha Akella; Andres Buonanno
Journal:  Mol Psychiatry       Date:  2022-09-08       Impact factor: 13.437

Review 2.  Ketamine and the Future of Rapid-Acting Antidepressants.

Authors:  Lace M Riggs; Todd D Gould
Journal:  Annu Rev Clin Psychol       Date:  2021-02-09       Impact factor: 18.561

Review 3.  Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants.

Authors:  Bashkim Kadriu; Maximillian Greenwald; Ioline D Henter; Jessica R Gilbert; Christoph Kraus; Lawrence T Park; Carlos A Zarate
Journal:  Int J Neuropsychopharmacol       Date:  2021-01-20       Impact factor: 5.176

4.  Fine-tuning neural excitation/inhibition for tailored ketamine use in treatment-resistant depression.

Authors:  Rosalyn J Moran; Jessica R Gilbert; Erik D Fagerholm; Robert Leech; Steven Williams; Carlos A Zarate
Journal:  Transl Psychiatry       Date:  2021-05-29       Impact factor: 6.222

5.  Advances in neurochemical measurements: A review of biomarkers and devices for the development of closed-loop deep brain stimulation systems.

Authors:  Juan M Rojas Cabrera; J Blair Price; Aaron E Rusheen; Abhinav Goyal; Danielle Jondal; Abhijeet S Barath; Hojin Shin; Su-Youne Chang; Kevin E Bennet; Charles D Blaha; Kendall H Lee; Yoonbae Oh
Journal:  Rev Anal Chem       Date:  2020-12-31       Impact factor: 3.067

6.  An Integrative Approach to Ketamine Therapy May Enhance Multiple Dimensions of Efficacy: Improving Therapeutic Outcomes With Treatment Resistant Depression.

Authors:  Sherry-Anne Muscat; Glenn Hartelius; Courtenay Richards Crouch; Kevin W Morin
Journal:  Front Psychiatry       Date:  2021-11-24       Impact factor: 4.157

7.  Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial.

Authors:  Marijn Lijffijt; Nicholas Murphy; Sidra Iqbal; Charles E Green; Tabish Iqbal; Lee C Chang; Colin N Haile; Lorna C Hirsch; Nithya Ramakrishnan; Dylan A Fall; Alan C Swann; Rayan K Al Jurdi; Sanjay J Mathew
Journal:  Neuropsychopharmacology       Date:  2021-11-27       Impact factor: 8.294

8.  Investigating the Effects of Auditory and Vibrotactile Rhythmic Sensory Stimulation on Depression: An EEG Pilot Study.

Authors:  Abdullah A Mosabbir; Thenile Braun Janzen; Maryam Al Shirawi; Susan Rotzinger; Sidney H Kennedy; Faranak Farzan; Jed Meltzer; Lee Bartel
Journal:  Cureus       Date:  2022-02-24

9.  Key considerations in the pharmacological management of treatment-resistant depression.

Authors:  Mani Yavi; Ioline D Henter; Lawrence T Park; Carlos Zarate
Journal:  Expert Opin Pharmacother       Date:  2021-07-21       Impact factor: 3.889

10.  Ketamine and Attentional Bias Toward Emotional Faces: Dynamic Causal Modeling of Magnetoencephalographic Connectivity in Treatment-Resistant Depression.

Authors:  Jessica R Gilbert; Christina S Galiano; Allison C Nugent; Carlos A Zarate
Journal:  Front Psychiatry       Date:  2021-06-18       Impact factor: 4.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.